解剖学报

解剖学报 ›› 2015, Vol. 46 ›› Issue (6): 791-796.doi: 10.16098/j.issn.0529-1356.2015.06.011

• 肿瘤生物学 • 上一篇    下一篇

乳腺癌患者原发磷酸化信号转导与转录激活因子3活性和白细胞介素-17表达的临床意义

王菊1,2 张楠3 马志萍3 李一鑫3 张文杰3* 周宗瑶1*   

  1. 1. 石河子大学医学院组织学胚胎学教研室，新疆 石河子 832002; 2. 华中科技大学同济医学院计划生育研究所/生殖医学中心，武汉 430030; 3. 石河子大学医学院病理系新疆地方与民族高发病教育部重点实验室，新疆 石河子 832002
  • 收稿日期:2014-12-09 修回日期:2015-06-29 出版日期:2015-12-06 发布日期:2015-12-06
  • 通讯作者: 张文杰;周宗瑶 E-mail:zp-wj@shzu.edu.cn

Clinical significance of phosphorylated signal transducer and activator of transcription 3 activing and interleukin-17 in patients with breast cancer

WANG Ju 1,2 ZHANG Nan3 MA Zhi-ping3 LI Yi-xing3 ZHANG Wen-jie 3* ZHOU Zong-yao 1*   

  1. 1. Department of Histology and Embryology, Shihezi University School of Medical, Xinjiang Shihezi 832002, China;2. Institute of Planned Parenthood Research, Center for Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 3. Department of Pathology/Key Laboratories for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Xinjiang Shihezi 832002, China

  • Received:2014-12-09 Revised:2015-06-29 Online:2015-12-06 Published:2015-12-06
  • Contact: ZHANG Wen-jie ;ZHOU Zong-yao E-mail:zp-wj@shzu.edu.cn

摘要：

目的 探讨炎性信号通路磷酸化信号转导和转录激活因子3（p-STAT）的原发活化状态及下游细胞因子白细胞介素（IL）-17表达在乳腺癌发生和发展中的作用及其对预后的影响。 方法 运用免疫组织化学Envision两步法检测了379例乳腺癌患者以及匹配癌旁245例乳腺腺病中IL-17表达和原发性p-STAT3的活化状态，分析了它们与乳腺癌组织学分型、TNM分期、临床分期及预后的相关性。统计学分析：计量数据使用t检验法，计数数据使用χ2 检验法。结果 1. IL-17在乳腺癌中的阳性表达率为95.8%，显著高于乳腺腺病中的阳性表达率85.3%（χ2=21.363，P<0.001）；具有活性的p-STAT3在乳腺癌中的阳性率为93.6%，也显著高于乳腺腺病中的阳性率62.0%（χ2=97.702，P<0.001）。2. IL-17和p-STAT3在乳腺癌 (包括乳腺浸润性导管癌、乳腺浸润性小叶癌和腺导管原位癌分型) 中的阳性率与乳腺癌组织学分型无相关性（χ2=1.245, P=0.535＞0.05）。3. IL-17和p-STAT3在乳腺癌中的强阳性率分别与淋巴结的转移成正相关（IL-17: χ2=7.806, P<0.01; p-STAT3: χ2=4.053, P<0.05）。4. 在乳腺癌组织中，IL-17表达与p-STAT3活性呈正相关（rs=0.136, P<0.01）。 结论 原发增高的p-STAT3活性及高表达的炎性细胞因子IL-17可能协同作用，产生炎性微环境，从而参与乳腺癌的发生和发展。

关键词: 白细胞介素-17, 信号转导和转录激活因子3, 乳腺癌, 癌转移, 免疫组织化学, 人

Abstract:

Objective To investigate involvement of constitutively activated phosphorylated signal transducer and activator of transcription 3(p-STAT3) and the expression of its downstream inflammatory cytokine interleukin (IL)-17 in the pathogenesis and progression in patients with breast cancer(BC). Methods Using specific antibodies, the levels of IL-17 and p-STAT3 were tested in 379 cases of breast cancer tissues (test group) and 245 cases of matching non-cancerous adjacent breast adinosis tissues (control group) using immunohistochemistry (IHC). The correlations of expressed IL-17 and active p-STAT3 were analyzed against breast cancer patients’ histological type, TNM and clinical stage, and progression, respectively. Quantitative data were analyzed using t test and qualitative data were analyzed using χ2 test. Results 1. IL-17 showed a positive expression rate of 95.8% in brest cancer tissues, higher than that of 85.3% in adenosis of breast tissues (χ2=21.36, P＜0.001); p-STAT3 exhibited a positive expression rate of 93.6% in BC tissues, much higher than that of 62.0% in adenosis of breast tissues (χ2=97.7，P<0.001). 2. The expressed IL-17 and active p-STAT3 were not correlated with histologic types of breast cancer (including invasive ductual carcinoma, invasive lobulao carcinoma, ductual carcinoma in situof breast) (χ2=1.245, P=0.535). 3. However, IL-17 and p-STAT3 were respectively correlated with lymph node metastasis in patients with BC (χ2=7.806, P<0.01; χ2=4.053, P<0.05, respectively). 4. In breast cancer tissues, the expression of IL-17 was positively correlated with activated p-STAT ( rs=0.136, P<0.01). Conclusion The constitutively over-active p-STAT3 and over-expressed IL-17 may collaborate to orchestrate an inflammatory microenvironment which, in turn, facilitates the pathogenesis and progression of breast cancer.

Key words: Interleukin-17, Phosphorylated signal transducer and activator of transcription 3, Breast cancer, Metastasis, Immunohistochemistry, Human